Condensed Consolidated Financial Information for Guarantor Subsidiaries and Non-Guarantor Subsidiaries - Condensed Consolidating Statement of Cash Flows (Detail) (USD $) | 12 Months Ended |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | ' | ' | ' |
Net cash (used in) provided by operating activities | $506,920,000 | $468,229,000 | $375,721,000 |
Cash flows from investing activities: | ' | ' | ' |
Acquisitions, net of cash acquired for 2012, 2011 and 2010 of $36,113 $590 and $10,524 respectively | -983,000 | -769,513,000 | -121,721,000 |
Earnout payments | 0 | 250,000 | 3,500,000 |
Purchase of non-controlling equity investments in non-public companies | 0 | -2,250,000 | 0 |
Escrow funding associated with acquisitions | 0 | -38,800,000 | -19,560,000 |
Proceeds from release of acquisition related escrows | 280,000 | 1,455,000 | 0 |
Repayments received from other subsidiaries | 0 | 0 | 0 |
Advances provided to other subsidiaries | 0 | 0 | 0 |
Proceeds from repayment of intercompany note receivable | ' | ' | 0 |
Purchases of fixed assets | -145,976,000 | -74,373,000 | -59,829,000 |
Purchases of available-for-sale securities | -5,870,000 | -1,784,000 | -1,549,000 |
Proceeds from sales and maturities of available-for-sale securities | 7,484,000 | 1,932,000 | 1,730,000 |
Other investing activities, net | -561,000 | ' | 300,000 |
Net cash used in investing activities | -145,626,000 | -883,583,000 | -204,129,000 |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of long-term debt, net of original issue discount | 0 | 347,224,000 | 696,559,000 |
Repayment of short-term debt refinanced on a long-term basis | 0 | 347,224,000 | 440,000,000 |
Repayment of current portion of long-term debt | ' | ' | -125,000,000 |
Proceeds from issuance of common stock | 0 | ' | ' |
Proceeds from issuance of short-term debt with original maturities greater than three months | ' | ' | 120,000,000 |
Proceeds from short-term debt, net | -10,000,000 | 357,224,000 | 10,000,000 |
Payment of debt issuance costs | -605,000 | -3,905,000 | -7,835,000 |
Repayment of current portion of long-term debt | -180,000,000 | 0 | -125,000,000 |
Repayments of advances provided to other subsidiaries | ' | ' | 0 |
Funds transferred due to merger | 0 | ' | ' |
Repayments of advances to other subsidiaries | 0 | 0 | ' |
Repayment of intercompany note payable | ' | ' | 0 |
Advances received from other subsidiaries | 0 | 0 | 0 |
Excess tax benefits from exercised stock options | 109,946,000 | 60,672,000 | 53,195,000 |
Proceeds from stock options exercised | 80,368,000 | 68,388,000 | 43,345,000 |
Other financing activities, net | -6,770,000 | -6,549,000 | -3,268,000 |
Net cash (used in) provided by financing activities | -284,472,000 | 313,555,000 | -34,780,000 |
Effect of exchange rate changes | -840,000 | 15,000 | -183,000 |
(Decrease) increase in cash and cash equivalents | 75,982,000 | -101,784,000 | 136,629,000 |
Cash and cash equivalents, beginning of period | 89,819,000 | 191,603,000 | 54,974,000 |
Cash and cash equivalents, end of period | 165,801,000 | 89,819,000 | 191,603,000 |
Supplemental disclosures: | ' | ' | ' |
Increase in intercompany balances from the purchase of MediConnect and Argus by ISO | ' | 0 | ' |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 0 | 0 | 0 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 0 | 0 | 0 |
Issuance of intercompany note payable (receivable) from amounts previously recorded as intercompany payables (receivables) | ' | ' | 0 |
Verisk Class A [Member] | ' | ' | ' |
Cash flows from financing activities: | ' | ' | ' |
Repurchases of Class A common stock | 277,411,000 | 162,275,000 | 381,776,000 |
Repayment of current portion of long-term debt | -180,000,000 | ' | ' |
Verisk Analytics, Inc. [Member] | ' | ' | ' |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | ' | ' | ' |
Net cash (used in) provided by operating activities | 42,000 | -20,115,000 | -14,821,000 |
Cash flows from investing activities: | ' | ' | ' |
Acquisitions, net of cash acquired for 2012, 2011 and 2010 of $36,113 $590 and $10,524 respectively | 0 | 0 | 0 |
Earnout payments | ' | 0 | 0 |
Purchase of non-controlling equity investments in non-public companies | 0 | -250,000 | ' |
Escrow funding associated with acquisitions | ' | 0 | 0 |
Proceeds from release of acquisition related escrows | 66,000 | 0 | ' |
Repayments received from other subsidiaries | 0 | 19,400,000 | 0 |
Advances provided to other subsidiaries | -30,000,000 | 0 | -10,052,000 |
Proceeds from repayment of intercompany note receivable | ' | ' | 0 |
Purchases of fixed assets | 0 | 0 | 0 |
Purchases of available-for-sale securities | 0 | 0 | 0 |
Proceeds from sales and maturities of available-for-sale securities | 0 | 0 | 0 |
Other investing activities, net | 0 | ' | 0 |
Net cash used in investing activities | -29,934,000 | 19,150,000 | -10,052,000 |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of long-term debt, net of original issue discount | ' | 347,224,000 | 696,559,000 |
Repayment of short-term debt refinanced on a long-term basis | ' | 0 | 0 |
Repayment of current portion of long-term debt | ' | ' | 0 |
Proceeds from issuance of short-term debt with original maturities greater than three months | ' | ' | 0 |
Proceeds from short-term debt, net | 0 | 0 | 0 |
Payment of debt issuance costs | 0 | -2,557,000 | -4,487,000 |
Repayments of advances provided to other subsidiaries | ' | ' | -7,204,000 |
Funds transferred due to merger | 0 | ' | ' |
Repayments of advances to other subsidiaries | -10,010,000 | -419,812,000 | ' |
Repayment of intercompany note payable | ' | ' | -617,796,000 |
Advances received from other subsidiaries | 60,000,000 | 0 | 34,038,000 |
Excess tax benefits from exercised stock options | 0 | 0 | 0 |
Proceeds from stock options exercised | 0 | 0 | 0 |
Other financing activities, net | 0 | 0 | 0 |
Net cash (used in) provided by financing activities | 49,990,000 | -75,145,000 | 101,110,000 |
Effect of exchange rate changes | 0 | 0 | 0 |
(Decrease) increase in cash and cash equivalents | 20,098,000 | -76,110,000 | 76,237,000 |
Cash and cash equivalents, beginning of period | 128,000 | 76,238,000 | 1,000 |
Cash and cash equivalents, end of period | 20,226,000 | 128,000 | 76,238,000 |
Supplemental disclosures: | ' | ' | ' |
Increase in intercompany balances from the purchase of MediConnect and Argus by ISO | ' | 17,000,000 | ' |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 277,411,000 | 162,275,000 | 381,776,000 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 80,368,000 | 68,388,000 | 43,345,000 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | 0 | ' | ' |
Issuance of intercompany note payable (receivable) from amounts previously recorded as intercompany payables (receivables) | ' | ' | 615,000,000 |
Verisk Analytics, Inc. [Member] | Verisk Class A [Member] | ' | ' | ' |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of common stock | 0 | ' | ' |
Repurchases of Class A common stock | 0 | 0 | 0 |
Repayment of current portion of long-term debt | 0 | ' | ' |
Guarantor Subsidiaries [Member] | ' | ' | ' |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | ' | ' | ' |
Net cash (used in) provided by operating activities | 287,956,000 | 329,845,000 | 346,820,000 |
Cash flows from investing activities: | ' | ' | ' |
Acquisitions, net of cash acquired for 2012, 2011 and 2010 of $36,113 $590 and $10,524 respectively | -983,000 | -762,596,000 | -121,721,000 |
Earnout payments | ' | 0 | 0 |
Purchase of non-controlling equity investments in non-public companies | -350,000 | -2,000,000 | ' |
Escrow funding associated with acquisitions | ' | -38,000,000 | -19,560,000 |
Proceeds from release of acquisition related escrows | 214,000 | 1,455,000 | ' |
Repayments received from other subsidiaries | 206,282,000 | 592,356,000 | 9,714,000 |
Advances provided to other subsidiaries | -68,692,000 | -52,000,000 | -54,701,000 |
Proceeds from repayment of intercompany note receivable | ' | ' | 617,796,000 |
Purchases of fixed assets | -118,307,000 | -60,525,000 | -50,813,000 |
Purchases of available-for-sale securities | -5,870,000 | -1,784,000 | -1,549,000 |
Proceeds from sales and maturities of available-for-sale securities | 7,484,000 | 1,932,000 | 1,730,000 |
Other investing activities, net | -561,000 | ' | 300,000 |
Net cash used in investing activities | 19,217,000 | -321,162,000 | 381,196,000 |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of long-term debt, net of original issue discount | ' | 0 | 0 |
Repayment of short-term debt refinanced on a long-term basis | ' | 347,224,000 | 440,000,000 |
Repayment of current portion of long-term debt | ' | ' | -125,000,000 |
Proceeds from issuance of short-term debt with original maturities greater than three months | ' | ' | 120,000,000 |
Proceeds from short-term debt, net | -10,000,000 | 357,224,000 | 10,000,000 |
Payment of debt issuance costs | -605,000 | -1,348,000 | -3,348,000 |
Repayments of advances provided to other subsidiaries | ' | ' | -2,510,000 |
Funds transferred due to merger | 2,877,000 | ' | ' |
Repayments of advances to other subsidiaries | -9,605,000 | -19,400,000 | ' |
Repayment of intercompany note payable | ' | ' | 0 |
Advances received from other subsidiaries | 30,000,000 | 0 | 46,013,000 |
Excess tax benefits from exercised stock options | 109,946,000 | 60,672,000 | 53,195,000 |
Proceeds from stock options exercised | 80,368,000 | 68,388,000 | 43,345,000 |
Other financing activities, net | -6,478,000 | -5,931,000 | -2,746,000 |
Net cash (used in) provided by financing activities | -260,908,000 | -49,894,000 | -682,827,000 |
Effect of exchange rate changes | -741,000 | -31,000 | 48,000 |
(Decrease) increase in cash and cash equivalents | 45,524,000 | -41,242,000 | 45,237,000 |
Cash and cash equivalents, beginning of period | 35,571,000 | 76,813,000 | 31,576,000 |
Cash and cash equivalents, end of period | 81,095,000 | 35,571,000 | 76,813,000 |
Supplemental disclosures: | ' | ' | ' |
Increase in intercompany balances from the purchase of MediConnect and Argus by ISO | ' | 790,174,000 | ' |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 277,411,000 | 162,275,000 | 381,776,000 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 80,368,000 | 68,388,000 | 43,345,000 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | 85,953,000 | ' | ' |
Issuance of intercompany note payable (receivable) from amounts previously recorded as intercompany payables (receivables) | ' | ' | -615,000,000 |
Guarantor Subsidiaries [Member] | Verisk Class A [Member] | ' | ' | ' |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of common stock | 0 | ' | ' |
Repurchases of Class A common stock | 277,411,000 | 162,275,000 | 381,776,000 |
Repayment of current portion of long-term debt | -180,000,000 | ' | ' |
Non-Guarantor Subsidiaries [Member] | ' | ' | ' |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | ' | ' | ' |
Net cash (used in) provided by operating activities | 218,922,000 | 158,499,000 | 43,722,000 |
Cash flows from investing activities: | ' | ' | ' |
Acquisitions, net of cash acquired for 2012, 2011 and 2010 of $36,113 $590 and $10,524 respectively | 0 | -6,917,000 | 0 |
Earnout payments | ' | 250,000 | 3,500,000 |
Purchase of non-controlling equity investments in non-public companies | 0 | 0 | ' |
Escrow funding associated with acquisitions | ' | -800,000 | 0 |
Proceeds from release of acquisition related escrows | 0 | 0 | ' |
Repayments received from other subsidiaries | 9,605,000 | 0 | 0 |
Advances provided to other subsidiaries | 0 | 0 | -81,824,000 |
Proceeds from repayment of intercompany note receivable | ' | ' | 0 |
Purchases of fixed assets | -27,669,000 | -13,848,000 | -9,016,000 |
Purchases of available-for-sale securities | 0 | 0 | 0 |
Proceeds from sales and maturities of available-for-sale securities | 0 | 0 | 0 |
Other investing activities, net | 0 | ' | 0 |
Net cash used in investing activities | -18,064,000 | -21,815,000 | -94,340,000 |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of long-term debt, net of original issue discount | ' | 0 | 0 |
Repayment of short-term debt refinanced on a long-term basis | ' | 0 | 0 |
Repayment of current portion of long-term debt | ' | ' | 0 |
Proceeds from issuance of short-term debt with original maturities greater than three months | ' | ' | 0 |
Proceeds from short-term debt, net | 0 | 0 | 0 |
Payment of debt issuance costs | 0 | 0 | 0 |
Repayments of advances provided to other subsidiaries | ' | ' | 0 |
Funds transferred due to merger | -2,877,000 | ' | ' |
Repayments of advances to other subsidiaries | -196,272,000 | -172,544,000 | ' |
Repayment of intercompany note payable | ' | ' | 0 |
Advances received from other subsidiaries | 8,692,000 | 52,000,000 | 66,526,000 |
Excess tax benefits from exercised stock options | 0 | 0 | 0 |
Proceeds from stock options exercised | 0 | 0 | 0 |
Other financing activities, net | -292,000 | -618,000 | -522,000 |
Net cash (used in) provided by financing activities | -190,399,000 | -121,162,000 | 66,004,000 |
Effect of exchange rate changes | -99,000 | 46,000 | -231,000 |
(Decrease) increase in cash and cash equivalents | 10,360,000 | 15,568,000 | 15,155,000 |
Cash and cash equivalents, beginning of period | 54,120,000 | 38,552,000 | 23,397,000 |
Cash and cash equivalents, end of period | 64,480,000 | 54,120,000 | 38,552,000 |
Supplemental disclosures: | ' | ' | ' |
Increase in intercompany balances from the purchase of MediConnect and Argus by ISO | ' | 773,174,000 | ' |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 0 | 0 | 0 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 0 | 0 | 0 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | -85,953,000 | ' | ' |
Issuance of intercompany note payable (receivable) from amounts previously recorded as intercompany payables (receivables) | ' | ' | 0 |
Non-Guarantor Subsidiaries [Member] | Verisk Class A [Member] | ' | ' | ' |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of common stock | 350,000 | ' | ' |
Repurchases of Class A common stock | 0 | 0 | 0 |
Repayment of current portion of long-term debt | 0 | ' | ' |
Eliminating Entries [Member] | ' | ' | ' |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | ' | ' | ' |
Net cash (used in) provided by operating activities | 0 | 0 | 0 |
Cash flows from investing activities: | ' | ' | ' |
Acquisitions, net of cash acquired for 2012, 2011 and 2010 of $36,113 $590 and $10,524 respectively | 0 | 0 | 0 |
Earnout payments | ' | 0 | 0 |
Purchase of non-controlling equity investments in non-public companies | 350,000 | 0 | ' |
Escrow funding associated with acquisitions | ' | 0 | 0 |
Proceeds from release of acquisition related escrows | 0 | 0 | ' |
Repayments received from other subsidiaries | -215,887,000 | -611,756,000 | -9,714,000 |
Advances provided to other subsidiaries | 98,692,000 | 52,000,000 | 146,577,000 |
Proceeds from repayment of intercompany note receivable | ' | ' | -617,796,000 |
Purchases of fixed assets | 0 | 0 | 0 |
Purchases of available-for-sale securities | 0 | 0 | 0 |
Proceeds from sales and maturities of available-for-sale securities | 0 | 0 | 0 |
Other investing activities, net | 0 | ' | 0 |
Net cash used in investing activities | -116,845,000 | -559,756,000 | -480,933,000 |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of long-term debt, net of original issue discount | ' | 0 | 0 |
Repayment of short-term debt refinanced on a long-term basis | ' | 0 | 0 |
Repayment of current portion of long-term debt | ' | ' | 0 |
Proceeds from issuance of short-term debt with original maturities greater than three months | ' | ' | 0 |
Proceeds from short-term debt, net | 0 | 0 | 0 |
Payment of debt issuance costs | 0 | 0 | 0 |
Repayments of advances provided to other subsidiaries | ' | ' | 9,714,000 |
Funds transferred due to merger | 0 | ' | ' |
Repayments of advances to other subsidiaries | 215,887,000 | 611,756,000 | ' |
Repayment of intercompany note payable | ' | ' | 617,796,000 |
Advances received from other subsidiaries | -98,692,000 | -52,000,000 | -146,577,000 |
Excess tax benefits from exercised stock options | 0 | 0 | 0 |
Proceeds from stock options exercised | 0 | 0 | 0 |
Other financing activities, net | 0 | 0 | 0 |
Net cash (used in) provided by financing activities | 116,845,000 | 559,756,000 | 480,933,000 |
Effect of exchange rate changes | 0 | 0 | 0 |
(Decrease) increase in cash and cash equivalents | 0 | 0 | 0 |
Cash and cash equivalents, beginning of period | 0 | 0 | 0 |
Cash and cash equivalents, end of period | 0 | 0 | 0 |
Supplemental disclosures: | ' | ' | ' |
Increase in intercompany balances from the purchase of MediConnect and Argus by ISO | ' | 0 | ' |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 0 | 0 | 0 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 0 | 0 | 0 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | 0 | ' | ' |
Issuance of intercompany note payable (receivable) from amounts previously recorded as intercompany payables (receivables) | ' | ' | 0 |
Eliminating Entries [Member] | Verisk Class A [Member] | ' | ' | ' |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from issuance of common stock | -350,000 | ' | ' |
Repurchases of Class A common stock | 0 | 0 | 0 |
Repayment of current portion of long-term debt | $0 | ' | ' |